Evidence map›Paper›PMID 39416458›Full record

ArticleBiotechnology notes (Amsterdam, Netherlands)2022

A SynBio community comes of age: Political, academical, industrial, and societal developments in the Netherlands.

Darshak K Bhatt, Marjolein E Crooijmans, Jelmer Coenradij, Alicia Maciá Valero, Maarten Lubbers, Enrique Asin-Garcia, N Amy Yewdall, Sarah D'Adamo, Nico J Claassens, Sonja Billerbeck

Abstract read
In one paragraph

Article in Biotechnology notes (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Darshak K BhattDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, University of Groningen, the Netherlands.
Marjolein E CrooijmansMicrobial Sciences, Institute of Biology Leiden, Leiden University, Leiden, the Netherlands.
Jelmer CoenradijDepartment of Biochemistry, Groningen Institute of Biomolecular Sciences & Biotechnology, University of Groningen, the Netherlands.
Alicia Maciá ValeroDepartment of Molecular Microbiology, University of Groningen, Groningen, the Netherlands.
Maarten LubbersMicrobial Sciences, Institute of Biology Leiden, Leiden University, Leiden, the Netherlands.
Enrique Asin-GarciaLaboratory of Systems and Synthetic Biology, Wageningen University & Research, Wageningen, the Netherlands.
N Amy YewdallInstitute for Molecules and Materials, Faculty of Science, Radboud University, Nijmegen, the Netherlands.
Sarah D'AdamoBioprocess Engineering, Wageningen University, Wageningen, the Netherlands.
Nico J ClaassensLaboratory of Microbiology, Wageningen University, Wageningen, the Netherlands.
Sonja BillerbeckDepartment of Molecular Microbiology, University of Groningen, Groningen, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Synthetic biology (SynBio) is a rapidly growing scientific discipline. In the Netherlands, various universities and companies are tackling a variety of opportunities and challenges within this field. In this perspective article, we review the current synthetic biology landscape in the Netherlands across academia, industry, politics, and society. Especially within Dutch academia there is an active, though only partially connected, research community involved in various domains of SynBio. Mostly supported by governmental funding, academic research is focusing on top-down synthetic biology, involving the engineering of, for example, bacteria and yeast for bioproduction, as well as bottom-up and cell-free synthetic biology aiming to understand life and build synthetic cells. There is also a large number of talented and motivated students interested in the field, exemplified by the participation and success of Dutch teams in the international iGEM synthetic biology competition. Commercial synthetic biology activities are taking place in various large industrial companies, as well as in start-ups and spin-offs, mostly divided over several 'SynBio hubs' in the Netherlands. However, the investment, regulatory and public-perception landscape is not yet optimal to stimulate entrepreneurial activities in SynBio. The Dutch and global society can further benefit from the large promise of SynBio through better integration of people active in the Dutch SynBio field, frequent political and public dialogue, and more attention towards regulatory issues. The recently founded Dutch synthetic biology association SynBioNL aims to contribute to realizing a positive impact on society by stimulating advances of the field in the Netherlands and beyond.

Indexed as

BioengineeringBiotechnologyCommunityDutch science fundingResearch landscapeScience and politicsScience communicationSynthetic biology

Identifiers

PMID39416458
PMCPMC11446357

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.